Gene therapies for osteoarthritis.

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Osteoarthritis (OA) is a major health problem in urgent need of better treatment. Gene therapy offers to meet this need. Of the different strategies for using gene therapy in OA, local gene transfer to synovium is in the most advanced stage of development. Local gene transfer brings several advantages, including a focused, local therapy that promises greater efficacy with reduced side-effects, potentially at far lower cost. Moreover, its clinical feasibility has already been confirmed in two Phase I studies of gene therapy for rheumatoid arthritis. Although there are numerous candidate genes of potential use in treating OA genetically, considerable evidence identifies interleukin-1 (IL-1) as a key target. The existence of a natural antagonist, the IL-1 receptor antagonist (IL-1Ra), provides a means with which to inhibit its biologic actions. Clinical studies are suggested in which IL-1Ra complementary DNA is transferred to knee joints shortly before they are surgically replaced with prostheses. This will permit the ready assessment of the safety and efficiency of gene transfer and expression in the human OA knee, as well as permitting preliminary functional data to be obtained, as a prelude to phase II efficacy studies. At this point, the major barriers to progress are financial rather than intellectual or technical.

Original languageEnglish (US)
Pages (from-to)31-40
Number of pages10
JournalCurrent Rheumatology Reports
Volume6
Issue number1
StatePublished - Feb 2004
Externally publishedYes

Fingerprint

Osteoarthritis
Genetic Therapy
Interleukin-1 Receptors
Genes
Synovial Membrane
Knee Osteoarthritis
Knee Joint
Interleukin-1
Prostheses and Implants
Rheumatoid Arthritis
Complementary DNA
Safety
Gene Expression
Costs and Cost Analysis
Health
Therapeutics
Clinical Studies

ASJC Scopus subject areas

  • Rheumatology

Cite this

Gene therapies for osteoarthritis. / Evans, Christopher H.

In: Current Rheumatology Reports, Vol. 6, No. 1, 02.2004, p. 31-40.

Research output: Contribution to journalArticle

@article{8630d79566604a6ea1f5d06665aac1cf,
title = "Gene therapies for osteoarthritis.",
abstract = "Osteoarthritis (OA) is a major health problem in urgent need of better treatment. Gene therapy offers to meet this need. Of the different strategies for using gene therapy in OA, local gene transfer to synovium is in the most advanced stage of development. Local gene transfer brings several advantages, including a focused, local therapy that promises greater efficacy with reduced side-effects, potentially at far lower cost. Moreover, its clinical feasibility has already been confirmed in two Phase I studies of gene therapy for rheumatoid arthritis. Although there are numerous candidate genes of potential use in treating OA genetically, considerable evidence identifies interleukin-1 (IL-1) as a key target. The existence of a natural antagonist, the IL-1 receptor antagonist (IL-1Ra), provides a means with which to inhibit its biologic actions. Clinical studies are suggested in which IL-1Ra complementary DNA is transferred to knee joints shortly before they are surgically replaced with prostheses. This will permit the ready assessment of the safety and efficiency of gene transfer and expression in the human OA knee, as well as permitting preliminary functional data to be obtained, as a prelude to phase II efficacy studies. At this point, the major barriers to progress are financial rather than intellectual or technical.",
author = "Evans, {Christopher H}",
year = "2004",
month = "2",
language = "English (US)",
volume = "6",
pages = "31--40",
journal = "Current Rheumatology Reports",
issn = "1523-3774",
publisher = "Current Science, Inc.",
number = "1",

}

TY - JOUR

T1 - Gene therapies for osteoarthritis.

AU - Evans, Christopher H

PY - 2004/2

Y1 - 2004/2

N2 - Osteoarthritis (OA) is a major health problem in urgent need of better treatment. Gene therapy offers to meet this need. Of the different strategies for using gene therapy in OA, local gene transfer to synovium is in the most advanced stage of development. Local gene transfer brings several advantages, including a focused, local therapy that promises greater efficacy with reduced side-effects, potentially at far lower cost. Moreover, its clinical feasibility has already been confirmed in two Phase I studies of gene therapy for rheumatoid arthritis. Although there are numerous candidate genes of potential use in treating OA genetically, considerable evidence identifies interleukin-1 (IL-1) as a key target. The existence of a natural antagonist, the IL-1 receptor antagonist (IL-1Ra), provides a means with which to inhibit its biologic actions. Clinical studies are suggested in which IL-1Ra complementary DNA is transferred to knee joints shortly before they are surgically replaced with prostheses. This will permit the ready assessment of the safety and efficiency of gene transfer and expression in the human OA knee, as well as permitting preliminary functional data to be obtained, as a prelude to phase II efficacy studies. At this point, the major barriers to progress are financial rather than intellectual or technical.

AB - Osteoarthritis (OA) is a major health problem in urgent need of better treatment. Gene therapy offers to meet this need. Of the different strategies for using gene therapy in OA, local gene transfer to synovium is in the most advanced stage of development. Local gene transfer brings several advantages, including a focused, local therapy that promises greater efficacy with reduced side-effects, potentially at far lower cost. Moreover, its clinical feasibility has already been confirmed in two Phase I studies of gene therapy for rheumatoid arthritis. Although there are numerous candidate genes of potential use in treating OA genetically, considerable evidence identifies interleukin-1 (IL-1) as a key target. The existence of a natural antagonist, the IL-1 receptor antagonist (IL-1Ra), provides a means with which to inhibit its biologic actions. Clinical studies are suggested in which IL-1Ra complementary DNA is transferred to knee joints shortly before they are surgically replaced with prostheses. This will permit the ready assessment of the safety and efficiency of gene transfer and expression in the human OA knee, as well as permitting preliminary functional data to be obtained, as a prelude to phase II efficacy studies. At this point, the major barriers to progress are financial rather than intellectual or technical.

UR - http://www.scopus.com/inward/record.url?scp=2142640339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2142640339&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 31

EP - 40

JO - Current Rheumatology Reports

JF - Current Rheumatology Reports

SN - 1523-3774

IS - 1

ER -